Cell and Gene Therapy: Oncology Clinical Trial Trends in the United States
By GD50 Custom
Cell and gene therapies (CGT) have seen expansive clinical development and revenue growth over the past 5 years across various therapeutic areas.
With the approval of 12 new therapies and the initiation of over 2,900 clinical trials between the analysis period of 2016 -2021, it is evident there is extensive investment in the innovation of CGT. Notably, oncology is the leading therapeutic area, with the highest percentage of new clinical development year-on year compared to other CGT therapy areas, indicating a high level of unmet needs and increased industry investment in the space.
Access GlobalData’s new whitepaper, Cell and Gene Therapy: Oncology Clinical Trial Trends in the United States to gain a better understanding of the developments, challenges and opportunities in CGT including exclusive insights on promising future oncology CGT assets in development.
The white paper covers:
- The key takeaways of cell and gene therapy
- Extensive background on the uptake of cell and gene therapy
- Insights and outlook of cell and gene therapy trials in the US
- An analysis of the top oncology cell and gene therapy assets and developers